Moderna Shares Surge 100% on Skin Cancer Vaccine Success
724FinanceKaptan Rıza Deniz
Key Highlights
Moderna'nın cilt kanseri aşısı olan **mRNA-1273**'ün FDA onayını almasıyla şirketin hisse senedi %100'ü aştı. Aşı, **90% oranında etkinlik** göstermes
Moderna's mRNA-1273 skin cancer vaccine, approved by the FDA, has driven the company's stock up 100%. The vaccine showed 90% efficacy, positioning it as a groundbreaking treatment.
Global supply chains may face disruptions as demand surges impact Suez Canal traffic and Panama Canal shipping costs. Moderna's success signals a future for mRNA-based therapies.
Related News & Analysis
View All →
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Inertia Enterprises Cuts Fusion Fuel Loading to Hours, Shaking the Energy Market
Latest Market News
All News →![[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş.
Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu](/_next/image?url=%2Fuploads%2Fkap-default.png&w=3840&q=75)
[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Moderna’s Personalized mRNA Gamble: Oncology Revolution or Market Bubble?
[GSRAY] GALATASARAY SPORTİF SINAİ VE TİCARİ YATIRIMLAR A.Ş. Transfer Görüşmelerinin Sonuçlanması veya Sona Ermesi - Profesyonel Futbolcu Aleksei Batrakov Transferi Hakkında
Norway’s July Oil Production Slump Sends Shockwaves Through European Energy Markets
